



Healthcare AI: Pilot Updates & Forward Agenda

Discussion with the Medical Licensure Board

Doctronic Pilot: Early Data

Request to the Board: help us assess how current pilots are performing.

- Clinician reviewers agreeing with AI recommendations as often as they agree with each other.
- Independent 3rd party evaluation initiated
- System generally showing overcaution, which is good
- Analysis on each disagreement case suggested generally mild risk levels

Pilot enhancements

- Third-party validation of reported data
- Improved EHR and continuity of care requirements
- Terms and conditions updates to clarify liability
- One drug removed from formulary
- Clarification of process on certain drugs
- Inquiry about personnel involved

Healthcare AI Advisory Group

A balanced slate of clinicians, researchers, and policy experts

This is a partial listing

Adam Bress, PharmD, MS

Professor, Population Health Sciences — Univ. of Utah

Nina De Lacy, MD, MBA, MA

Assistant Professor — Univ. of Utah

Viet Le, PA-C, DMSc

Assoc. Professor, Cardiovascular Research — Intermountain Health

Kasey Shakespear, MHA, MPH, MA

Executive Director — Rural Health Assn. of Utah

Ted Cho, MD, MBA

Pediatric Emergency Medicine Fellow — Boston Children's

Kate Eisenberg, MD, PhD, FAAFP

Senior Medical Director, Dyna AI — EBSCO

Mark Sendak, MD, MPP

Co-Founder & CEO — Vega Health

Nirav R. Shah, MD, MPH

Senior Scholar — Stanford University

Rep. Jennifer Dailey-Provost, MBA, PhD

Minority Whip — Utah House of Representatives

Michelle Mello, JD, PhD, MPhil

Professor of Health Policy & Law — Stanford University

Lucy Orr Ewing

Director of Strategy & Policy — Coalition for Health AI

Ryan Morley

Partner — SpringTide Ventures



**Request: Help us evaluate ~40
new pilot proposals**

Long-Term Regulatory Hypotheses

Ask: help us evaluate these models

Collaborative Practice

AI under physician collaboration and oversight

Clinical Trial Framework

Evidence from structured, monitored trials


Physician Licensure

Training (FDA-evaluated), digital residency (state-monitored), and ongoing DOPL enforcement

AI Lifecycle Management

Oversight across the full model lifecycle, adverse outcome monitoring, model drift assessment, bias assessment, etc.

Healthcare AI Learning Agenda

A bright yellow L-shaped decorative bar is positioned in the bottom right corner of the slide, extending from the right edge and the bottom edge.

Risks Identified

Concerns raised across stakeholder engagement

**Poor-quality AI
implementation
and oversight**

**Disintermediation
of trusted
providers**

“Just more EHR”

**Patient harms
from AI
misinformation**

**Transition
difficulties for
rural systems**

**Patient data use
and consent**

Benefits Available Now

Delivering value to clinicians and patients today
(when done well)

Ambient Listening

Note-taking from the
visit conversation



OpenEvidence

Evidence-based
answers at point of care



Direct-to-Patient Information

Tailored health
information to support
patients



Paperwork & Compliance

Drafting, coding,
documentation support



Policy Areas Stakeholders Asked Us to Examine

Practice & Accountability

- Liability
- Professional conduct standards
- Unlicensed practice

Access, Payment & Data

- Direct-to-consumer care
- Reimbursability
- Data privacy

Request to the Board: we welcome your policy input on these areas for our learning agenda.



Thank you

Dr. Zach Boyd: zboyd@utah.gov